Ann: Neurizon to present at Annual ALS Drug Development Summit, page-16

".........What is most interesting is the non-highlighted 'readouts',............"

As you say Densy, these pre-clinicals could well be showing signs of NUZ-001 entering "disease modifying" territory......Wow.
Re the non-highlighted readouts. Towards the end of the video (around the 1:09 mark) MT is answering a question re the preclinical tests and when we can expect results. He once again points out the importance of the tests and that is why their results are being verified by running the tests AGAIN! He states that this is important for patent applications, but also for publications and potential partners. I doubt poor results would be important for any of these. Also, as you point out, the non-highlighted results are likely to be the work ongoing at Ncardia. IMO these are the tests which MT referred to as being duplicated to verify results. I.e. they have been privy to the first batch of readouts already and decided that they had better make bloody sure that they weren't just a fluke before publishing them!

To ME, in the intro letter for the presentation slides seems to indicate that at least some of these results are indeed already known. But, I assume being verified (hence not highlighted in the slides). i.e. To my knowledge we haven't seen an official ASX announcement yet which covers all of these bullet points. More just hints that we MAY be seeing positive signs, but that more pre-clinical tests are being arranged to verify them. I may have misinterpreted this of course and it is different pre-clinical tests which are now being run.
Either way, the bullet point list is pretty impressive to say the least.